Skip to content

SSERS-Nanoprobes/ SERS Chip platforms for medical diagnostic testing of biological marker in breast cancer tumor sample

SERS-Nanoprobes/ SERS Chip platforms for Multiplexed Diagnosis of Breast Cancer Biomarkers in Tumor Tissue Samples.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/03/031978
Enrollment
200
Registered
2021-03-15
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C50- Malignant neoplasm of breast

Interventions

Intervention1: SERS-Nanoprobes/ SERS Chip platforms: 2) Multiplex, SERS-based immuno-assay, SERS- nanotags as target biomarker against antibody labelled and SERS chips, as label-free detection platfor

Sponsors

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Male or female with histopathological proven diagnosis of breast carcinoma.

Exclusion criteria

Exclusion criteria: NA

Design outcomes

Primary

MeasureTime frame
. OBJECTIVES: 1) Develop nanobiosensor platforms and associated technologies for easy differential screening and detection of breast (ER, PR, HER-2 & Ki67) biomarkers 2) Multiplex, SERS-based immuno-assay, SERS- nanotags as target biomarker against antibody labelled and SERS chips, as label-free detection platform for sensitive and specific detection of the predictive markers in tumor tissue (micro-environment) Timepoint: Baseline

Secondary

MeasureTime frame
1) Develop nanobiosensor platforms and associated technologies for easy differential screening and detection of breast (ER, PR, HER-2 & Ki67) biomarkers 2) Multiplex, SERS-based immuno-assay, SERS- nanotags as target biomarker against antibody labelled and SERS chips, as label-free detection platform for sensitive and specific detection of the predictive markers in tumor tissue (micro-environment) Timepoint: Baseline

Countries

India

Contacts

Public ContactYogesh Kembhavi

Tata Memorial Centre

sudeepgupta04@yahoo.com02224177201

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026